Background: The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors. 
INTRODUCTION
Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase with an IC50 of approximately 20-50 nM in an ATPindependent fashion. [1] [2] [3] [4] [5] [6] More recent publications suggest a c-Met for tivantinib, with the most common adverse events in the first 175 patients treated being fatigue (42.9%), nausea (28.6%), vomiting (21.1%), anemia (18.3%), anorexia (16.0%), diarrhea (15.4%), pyrexia (12.0%), peripheral edema (11.4%), abdominal pain (10.3%), and back pain (10.9%). In addition, there were a total of 17 episodes (all grade 1) of sinus bradycardia reported in 6 of 175 (3.4%) patients. Serious adverse events were uncommon (17; 5.1%) and included seven myelosuppression events in five patients and five gastrointestinal events in two patients. Dose-limiting toxicities (DLTs) from single-agent tivantinib included febrile neutropenia (2) , thrombocytopenia (1), leukopenia (1), neutropenia (1), vomiting (1), dehydration (1), fatigue (1), mucosal inflammation (1) , and palmar-plantar erythrodysesthesia syndrome (1). [7] [8] [9] [10] When considering the scope of pediatric and adolescent tumors affected by aberrant c-Met signaling, as well as the encouraging preliminary results of studies using c-Met inhibition strategies, 7, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] exploration of c-Met inhibition in pediatric patients has emerged as an important focus of clinical investigation.
We now report the results of a phase 1 trial of tivantinib in pediatric patients with relapsed or refractory solid tumors. Goals of this trial were to define a recommended dose for subsequent phase 2 pediatric studies, describe the pharmacokinetics (PKs) of tivantinib in pediatric patients when administered as either a solid or powder form with food, and do a preliminary investigation of any impact of CYP2C19 genotype and c-Met tumor expression on PK or clinical parameters.
MATERIALS AND METHODS

Patient eligibility
Eligible patients were more than 12 months and less than or equal to 21 years of age with a histologic diagnosis of cancer. Patients must have had either measurable or evaluable disease with no known curative therapy or therapy proven to prolong survival with an acceptable quality of life. Patients must have fully recovered from the acute toxic effects of all prior anticancer chemotherapy and have undergone appropriate washout periods for biologic or short-acting growth factors (7 days), long-acting growth factor (14 days), myelosuppressive chemotherapy (21 days), nitrosurea or immunotherapy (42 days), or monoclonal antibodies (three half-lives). At least 14 days must have elapsed since local palliative radiation (XRT) (small port) and at least 150 days must have elapsed in case of prior total body radiation (TBI), craniospinal XRT or 50% or more XRT of pelvis. At least 42 days must have elapsed if other substantial bone marrow XRT was given and 84 days since stem cell infusion without TBI. Patients may not have received prior therapy with tivantinib.
Organ function requirements included adequate bone marrow function (absolute neutrophil count ≥1,000/mm 3 and platelet count ≥100,000/mm 3 transfusion independent), defined as not receiving platelet transfusions for at least 7 days prior to enrollment. Patients with known bone marrow involvement were eligible for study but were not evaluable for hematologic toxicity provided they met these hematologic parameters with the exception of transfusion independence. In each cohort, at least five of every six patients with a solid tumor must have been evaluable for hematologic toxicity for the dose escalation part of the study. Adequate renal function (creatinine clearance [CL] or radioisotope glomerular filtration rate ≥70 ml/min/1.73 m 2 or predefined serum creatinine meeting ageappropriate levels) and adequate liver function, defined as bilirubin (sum of conjugated + unconjugated) less than or equal to 1.5 times the upper limit of normal for age, alanine aminotransferase (ALT) less than or equal to 110 U/L, and serum albumin 2 g/dL or more, were required. Exclusion criteria included pregnant or breast-feeding women, patients with active graft versus host disease, patients receiving corticosteroids who were not on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment, patients who were currently receiving another investigational drug or another anticancer agent or any of the following drugs: cyclosporine, tacrolimus or other agents to prevent graft versus host disease after bone marrow transplant, and CYP 2C19 substrates, inducers, or inhibitors for at least 24 hr prior to enrollment. Patients in Part A were required to be able to swallow capsules whole. Patients with an uncontrolled infection or who had received prior solid organ transplantation were excluded. In addition, patients with grade 2 or higher sinus bradycardia or with a known history grade 2 or higher cardiac arrhythmia were not eligible.
All patients and/or their parents or legally authorized representatives signed a written informed consent. Assent, when appropriate, was obtained according to institutional guidelines. All participating institutions were required to have protocol Institution Review Board approval prior to patient enrollments.
Trial design
The primary objectives of this study were to estimate the MTD and/or recommended phase 2 dose (RP2D) of tivantinib administered orally twice daily to children with refractory solid tumors, to define and describe the toxicities of tivantinib administered on this schedule, and to characterize the PKs of tivantinib (capsule as well as powder formulation) in children with refractory cancer. Secondary aims were to preliminarily define the antitumor activity of tivantinib within the confines of a phase 1 study, to preliminarily investigate whether CYP2C19 polymorphisms impact PKs or toxicity of tivantinib in pediatric subjects, and to preliminarily investigate whether tumor c-Met expression correlates with clinical response to tivantinib.
A rolling-six design was used for dose escalation, as previously described. 52 Nonhematologic DLT was defined as any grade 3 or 4 nonhematologic toxicity attributable to the investigational agent with the specific exclusion of grade 3 nausea and vomiting of less than 3 days duration, grade 3 liver enzyme elevation (ALT, aspartate aminotransferase, or gammaglutamyl transferase) that returns to levels that meet initial eligibility criteria or baseline within 7 days, grade 3 or 4 fever of less than 5 days duration, grade 3 infection of less than 5 days duration, and grade 3 hypophosphatemia, hypokalemia, hypocalcemia, or hypomagnesemia responsive to oral supplementation. Any grade 2 nonhematologic toxicity that persisted for 7 days, and was considered sufficiently medically significant or sufficiently intolerable by patients that it required treatment interruption, was considered a DLT. Hematologic DLT was defined in patients evaluable for hematologic toxicity as grade 4 thrombocytopenia (platelet count <25,000/mm 3 ) or grade 4 neutropenia not due to malignant infiltration. Grade 4 fever of less than 5 days duration, with or without grade 1-3 neutropenia, was not considered a DLT. 
Patient monitoring
Clinical (history, physical examination, and vital signs) and laboratory (complete blood counts with platelet and differential, electrolytes [including calcium, phosphorous, and magnesium], creatinine, ALT, bilirubin) assessments were required at least weekly during cycle 1.
Albumin levels were monitored every cycle. A 12-lead electrocardiogram was obtained prior to therapy initiation and 2-3 hr after the first dose on day 1 of cycle 1 in all patients.
Pharmacokinetics
Blood samples (2-3 mL) were collected in prechilled polyethylene tubes containing potassium ethylenediaminetetraacetic acid (EDTA).
After thorough mixing, plasma was separated by centrifugation 
Pharmacogenomics
Consenting patients provided whole blood (5 mL) in EDTA tubes prior to treatment in an attempt to correlate three CYP2C19 polymorphisms of interest with PKs, toxicity, and response to protocol therapy. The CYP2C19 phenotype was defined using a published algorithm. 53 
Pharmacodynamics
Tissue from original diagnosis, relapse, and/or any subsequent resections or biopsies prior to treatment on this protocol were submitted to Affiliated Pathology Services for tumor membranous c-Met expression analysis (Ventana antibody, catalog #790-4430). Tissue specimens (paraffin-embedded or fresh frozen tissue) were prioritized, but if a block was not available, then a minimum of 10 unstained slides were used for analyses. Scoring from 0 to 3 was provided for negative, weak, moderate, or strong scoring, respectively.
Criteria for assessment of response
Imaging studies to assess response were performed prior to the second cycle, every other cycle twice, and then every third cycle thereafter. Response assessments were based on revised response evaluation criteria in solid tumors (RECIST) criteria (version 1.1). 54 Standard RECIST definitions for the best response were incorporated and any partial response, complete response, or prolonged stable disease (greater than 6 months) required central radiology review.
TA B L E 1
Patient characteristics for eligible patients (n = 36)
Characteristics
Number (%)
Age ( 
RESULTS
Patients
Thirty-six patients were enrolled with a median age of 11.5 years Table 1 . Fifteen patients had primary central nervous system (CNS) tumors and 21 had solid tumors. All patients enrolled had at least one prior therapy including chemotherapy, XRT, or both.
Toxicities
Twenty-six patients were evaluable for toxicity assessment. 
Response
Of the 32 patients evaluable for response, 2 had stable disease as their *Observed in more than 10% of evaluable patients (n = 26). Toxicities that occurred in more than as determined in the first cycle of protocol therapy and attribution is in "PROBABLE," or "POSSIBLE," or "DEFINITE."
withdrawal of consent during cycle 1 (1), refusal prior to end of cycle 1 (1), DLT (intracranial hemorrhage) prior to end of cycle 1 (1), and rapid early progressive disease (1) . There were no objective responses to tivantinib therapy.
PKs and pharmacogenetics
Thirty-five patients participated in the PK study; the results are summarized in Table 4 , and a graph of AUC 0-8h versus BSA-adjusted dose is shown in Figure 1A . values was not observed (Table 4 and Fig. 1A ). Since the apparent oral CL could not be accurately calculated, the AUC 0-8h was normalized for the administered dose (AUC 0-8h /dose) to assess factors that might contribute to the high interpatient variability in PKs. The similar median AUC 0-8h /dose values across dose levels ( higher median exposure compared with tivantinib than the capsule formulation, though such differences were not statistically significant (P = 0.11) ( Table 4) . 
TUMOR C-MET EXPRESSION
Thirty-three patients had tissue available at enrollment and the tissue sample required for c-Met analysis was submitted for 32 of them.
One site discovered, after enrollment, that the tissue samples were not available and therefore could not submit them. Membranous and total c-Met expression was high (0), moderate (2), low (4), or not detected (26) . The two patients with stable disease had either low or undetectable c-Met expression.
DISCUSSION
The Met oncogene was first identified in 1984 in a chemically transformed osteosarcoma cell line. 55 Met encodes for a membranespanning receptor tyrosine kinase, which triggers multiple intracellular processes leading to proliferation, survival, motility, angiogenesis, and invasion. 56, 57 The sole ligand for c-Met is hepatocyte growth factor in some tumors such as hereditary renal papillary carcinoma, 61 and somatic mutations have also been documented in childhood hepatocellular carcinoma. 62 While tumors with activating mutations may be predicted to be most sensitive to c-Met inhibition, antitumor activity in preclinical settings has been demonstrated in models without defined mutations. 57 The varied mechanisms of activation and lack of redundancy of this pathway, together with effects on tumor-associated angiogenesis, suggest that a mutation may not necessarily be required in order to observe clinical benefit. Importantly, c-Met/HGF dysregulation in common pediatric solid tumors has been well described, with evidence of both c-Met and HGF overexpression, associations with poorer outcome and/or higher tumor grade, and with demonstrable impact on downstream tumor signaling impacting chemoresistance, tumor growth, tumor invasiveness, and tumor angiogenesis (Table 5) . 
